Category: 53838-27-0

On July 2, 2009, Manoharan, Muthiah; Rajeev, Kallanthottathil G.; Jayaraman, Muthusamy; Narayanannair, Jayaprakash K. published a patent.Name: (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate The title of the patent was Preparation of oligonucleotide-folate conjugates. And the patent contained the following:

The invention provides an iRNA agent having at least one monomer with the structure shown in formula I, where A and B are each independently O, imino groups, or S; X, Y are independently H, a protecting group, a phosphate, phosphodiester, activated phosphate or phosphite group, phosphoramidite, a solid support, -P(Z’)(Z”)O-nucleoside, -P(Z’)(Z”O)-oligonucleotide, a lipid, a PEG, a steroid, a polymer, -P(Z’)(Z”)O-L6-Q’-L7-OP(Z”’)(Z””)O-oligonucleotide, a nucleotide, or an oligonucleotide (Y may also be a lipophile); R is folate, a folate analog or mimic or a folate receptor-binding ligand; L6, L7 are independently -(CH2)n-, -CR’R”(CH2)n-, -(CH2)nCR’R”-, -(CH2CH2O)mCH2CH2-, or -(CH2CH2O)mCH2CH2NH-; Q’ is NH, O, S, CH2, CO2, CONH, NHCH(Ra)CO-, -COCH(Ra)NH-, CO, etc.; Ra is H or an amino acid side chain; R’, R” are independently H, Me, OH, SH, NH2, alkyl- or dialkylamino; Z’, Z”, Z”’, and Z”” are independently O or S; n is 1-20; and m is 0-50. The synthesis and biol. properties of oligonucleotide-folate conjugates are described. An example describes the synthesis of folate conjugate monomer II (CPG = controlled pore glass long-chain alkylamine, DMTr = 4,4′-dimethoxytrityl). A figure shows the in vivo targeting of folate-conjugated siRNAs. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).Name: (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate

The Article related to folate oligonucleotide conjugate preparation antitumor, Amino Acids, Peptides, and Proteins: Poly(Amino Acids) and Peptides and other aspects.Name: (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On March 26, 2009, Gellerman, Gary published a patent.SDS of cas: 53838-27-0 The title of the patent was Preparation of diketopiperazines and related heterocyclic scaffolds which are useful for the preparation of combinatorial libraries. And the patent contained the following:

The invention discloses heterocyclic scaffolds I [X, Y, Z are independently CH2 or CO; R1, R2 are (CH2)0-5CO2H or (CH2)0-5-Q1-P1 or (CH2)0-5-Q2-P2, resp.; R3 is (CO)0-1-A-CO2H or (CO)0-1-A-Q3-P3, where Q1, Q2, Q3 are linkers N, NH, O, or S; P1, P2, P3 are protecting groups; A is a linker (CH2)0-5, O(CH2)0-5, NH(CH2)0-5, -N-alkyl-(CH2)0-5, phenylene-(CH2)0-5, cyclopropylene-(CH2)0-5, cyclobutylene-(CH2)0-5, cyclopentylene-(CH2)0-5, cyclohexylene-(CH2)0-5, piperidinylene-(CH2)0-5, pyrrolene-(CH2)0-5; R4 is H or CH2 or CO attached to linker A], which are useful, for example, for the solid-phase organic synthesis of combinatorial libraries. Thus, I (X, Y are CO; Z-A-R3 is CH2CO2H; R1-CH2 is ornithine Alloc-protected side chain; R2-CH2 is lysine Fmoc-protected side chain; R4 is H) was prepared via peptide coupling in solution and heterocyclization (NMM in 2-butanol at reflux for 10 h). The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).SDS of cas: 53838-27-0

The Article related to peptide piperazinedione preparation scaffold combinatorial library, Amino Acids, Peptides, and Proteins: Poly(Amino Acids) and Peptides and other aspects.SDS of cas: 53838-27-0

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On October 31, 1993, Schwartz, Brenda L.; Erickson, Bruce W.; Bursey, Maurice M.; Marbury, G. Dean published an article.SDS of cas: 53838-27-0 The title of the article was Dependence of benzyl alcohol loss on C-terminal amino acid in tandem mass spectrometry of N-protected tripeptides. And the article contained the following:

The effect of the basicity and chain length of the C-terminal amino acid on the fragmentation of N-protected tripeptides was investigated with a hybrid tandem instrument. Pos.-ion unimol. decomposition and collisionally activated decomposition studies on the [M + H]+ ions of a series of N-benzyloxycarbonyl (Z)-protected tripeptides Z-Gly-Leu-Xxx-OMe and Z-Gly-Pro-Xxx-OMe (Xxx = Arg, Lys, Orn, Gln Glu) indicate that substitution of Leu with Pro at the second position in the tripeptides facilitates the loss of benzyl alc. (108 u) from the precursor. Addnl., higher gas-phase basicity and longer chain length of the C-terminal side-chain group promote the formation of the [M + H – 108]+ ion. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).SDS of cas: 53838-27-0

The Article related to protected tripeptide mass spectra, benzyloxycarbonyl tripeptide mass spectra, Amino Acids, Peptides, and Proteins: Poly(Amino Acids) and Peptides and other aspects.SDS of cas: 53838-27-0

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On January 31, 2002, Saksena, Anil K.; Girijavallabhan, Viyyoor Moopil; Lovey, Raymond G.; Jao, Edwin E.; Bennett, Frank; McCormick, Jinping; Wang, Haiyan; Pike, Russell E.; Bogen, Stephane L.; Liu, Yi-Tsung; Arasappan, Ashok; Parekh, Tejal; Pinto, Patrick A.; Njoroge, F. George; Ganguly, Ashit K.; Brunck, Terence K.; Kemp, Scott Jeffrey; Levy, Odile Esther; Lim-Wilby, Marguerita published a patent.Recommanded Product: (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate The title of the patent was Preparation of novel peptides as NS3-serine protease inhibitors of hepatitis C virus. And the patent contained the following:

Novel peptides I [Z = O, NH or substituted imino; X = (un)substituted alkylsulfonyl, heterocyclylsulfonyl, heterocyclylalkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, alkylcarbonyl, heterocyclylcarbonyl, heterocyclylalkylcarbonyl, arylcarbonyl, heteroarylcarbonyl, alkoxycarbonyl, heterocyclyloxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, alkyaminocarbonyl, heterocyclylaminocarbonyl, arylaminocarbonyl, or heteroarylaminocarbonyl; X1 = H, alkyl, arylmethyl; P1a, P1b, P2-P6 = H, (un)substituted alkyl, alkenyl, cycloalkyl, heterocyclyl, cycloalkylalkyl, heterocyclylalkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; P1a and P1b may optionally be joined to each other to form a spirocyclic or spiroheterocyclic ring containing 0-6 oxygen, nitrogen, sulfur, or phosphorus atoms; P1′ = H, (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, or heteroarylalkyl] having HCV protease inhibitory activity are disclosed. Thus, peptide II was prepared via peptide coupling in solution and showed Ki = 1-100 nM for inhibition of HCV protease. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).Recommanded Product: (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate

The Article related to peptide preparation ns3 serine protease inhibitor, hepatitis c virus treatment peptide, Amino Acids, Peptides, and Proteins: Poly(Amino Acids) and Peptides and other aspects.Recommanded Product: (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On November 7, 1984, Felix, Arthur Martin; Meienhofer, Johannes Arnold; Trzeciak, Arnold; Gillessen, Dieter; Studer, Rolf published a patent.Quality Control of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate The title of the patent was Intermediates for thymosin α1 and desacetylthymosin α1. And the patent contained the following:

R-Ser(CMe3)-Asp(OCMe3)-Ala-Ala-Val-Asp(OCMe3)-Thr(CMe3)-Ser(CMe3)-Ser(CMe3)-Glu(OCMe3)-OR1 [I; R = Ac, Me3CO2C (Boc); R1 = H, Ph] were prepared as intermediates for the synthesis of thymosin α1 (II, R2 = Ac) and desacetylthymosin α1 (II, R2 = H). Thus, Ac-Ser(CMe3)-Asp(OCMe3)-Ala-ONSu (III, NSu = succinimido) was coupled with H-Ala-Val-Asp(OCMe3)-Thr(CMe3)-Ser(CMe3)-Ser(CMe3)-Glu(OCMe3)-OPh (IV) to give I (R = Ac, R1 = Ph), which was saponified in the presence of H2O2 to give I (R = Ac, R1 = H) (V). Z-Ile-Thr(CMe3)-Thr(CMe3)-Lys(Boc)-Asp(OCMe3)-Leu-Lys(Boc)-Glu(OCMe3)-Lys(Boc)-Lys(Boc)-Glu(OCMe3)-Val-Val-Glu(OCMe3)-Glu(OCMe3)-Ala-Glu(OCMe3)-Asn-OCMe3 (VI, Z = PhCH2O2C) was Z-deblocked by hydrogenolysis and then coupled with V by DCC/1-hydroxybenzotriazole to give protected thymosin α1, which was deblocked by CF3CO2H to give II (R2 = H). VI was prepared by a series of fragment condensations from H-Glu(OCMe3)-Ala-Glu(OCMe3)-Asn-OCMe3 (VII), Z-Glu(OCMe3)-Val-Val-Glu(OCMe3)-OH (VIII), Z-Glu(OCMe3)-Lys(Boc)-Lys(Boc)-OH (IX), Z-Asp(OCMe3)-Leu-Lys(Boc)-OH (X), and Z-Ile-Thr(CMe3)-Thr(CMe3)-Lys(Boc)-OH (XI). III, IV, and VII-XI were prepared by conventional solution methods. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).Quality Control of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate

The Article related to thymosin preparation peptide intermediate, desacetylthymosin preparation peptide intermediate, Amino Acids, Peptides, and Proteins: Poly(Amino Acids) and Peptides and other aspects.Quality Control of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On February 7, 2013, Babich, John W.; Zimmerman, Craig; Joyal, John L.; Lu, Genliang published a patent.Category: esters-buliding-blocks The title of the patent was Preparation of radiolabeled prostate specific membrane antigen inhibitors, particularly glutamate-urea-glutamates and glutamate-urea-lysines and their radionuclides conjugates, for diagnosis and treatment of diseases. And the patent contained the following:

The invention is related to the preparation of glutamate-urea-lysine (GUL) or glutamate-urea-glutamate (GUG) analogs in which a chelator group is conjugated to the GUL or GUG moiety via a linker, e.g., I, that are potent inhibitors of PSMA activity and to their radionuclides conjugates useful for treating or diagnosis of a disease or a condition associated with PSMA activity. Thus, I and its 111Lu-complex were prepared Biodistribution studies and affinity binding tests were conducted for the 111Lu complex. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).Category: esters-buliding-blocks

The Article related to glutamate urea lysine peptide linker radionuclide conjugate psma inhibitor, radionuclide glutamate urea homodimer conjugate preparation tracer imaging agent, Amino Acids, Peptides, and Proteins: Poly(Amino Acids) and Peptides and other aspects.Category: esters-buliding-blocks

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On August 7, 2019, Muramatsu, Wataru; Hattori, Tomohiro; Yamamoto, Hisashi published an article.Electric Literature of 53838-27-0 The title of the article was Substrate-directed Lewis-acid catalysis for peptide synthesis. And the article contained the following:

A Lewis-acid-catalyzed method for the substrate-directed formation of peptide bonds has been developed, and this powerful approach is utilized for the new “remote” activation of carboxyl groups under solvent-free conditions. The presented method has the following advantages: (1) the high-yielding peptide synthesis uses a tantalum catalyst for any amino acids; (2) the reaction proceeds without any racemization; (3) the new substrate-directed chem. ligation using the titanium catalyst is applicable to convergent peptide synthesis. These advantages overcome some of the unresolved problems in classical peptide synthesis. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).Electric Literature of 53838-27-0

The Article related to peptide synthesis substrate directed lewis acid catalysis tantalum racemization, substrate directed ligation titanium catalyst solvent free neutralization solubility, Amino Acids, Peptides, and Proteins: Poly(Amino Acids) and Peptides and other aspects.Electric Literature of 53838-27-0

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On December 31, 2006, Kondratenko, R. M.; Baltina, L. A. Jr.; Baltina, L. A.; Baschenko, N. Zh.; Tolstikov, G. A. published an article.Product Details of 53838-27-0 The title of the article was Synthesis and immunomodulating activity of new glycopeptides of glycyrrhizic acid containing residues of L-glutamic acid. And the article contained the following:

New glycopeptides of glycyrrhizic acid [i.e., GA; (3β,20β)-20-carboxy-11-oxo-30-norolean-12-en-3-yl-2-O-β-D-glucopyranuronosyl-α-D-glucopyranosiduronic acid], containing Glu residues and their α-Me esters, γ-Me esters, and α,γ-di-Me esters were synthesized using N,N’-dicyclohexylcarbodiimide in the presence of N-hydroxybenzotriazole or N-hydroxysuccinimide. Formation of amide bonds was observed on all the three COOH groups of GA, or selectively on the COOH groups of the GA carbohydrate part in dependence on the ratio of reagents and the reaction conditions. The GA glycopeptide with three residues of Glu(OH)-OMe at a dose of 2 mg/kg stimulated the production of antibody-forming cells in mouse spleen in comparison with the control. The GA glycopeptide containing Glu residues only in the GA carbohydrate part turned out to be an immunosuppressor. The glycopeptide of the 30-Me ester of GA with residues of free Glu in its carbohydrate part increased the hemagglutinin titer at oral doses of 2 and 10 mg/kg. All the studied compounds had practically no effect on the delayed-type hypersensitivity in mice. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).Product Details of 53838-27-0

The Article related to immunomodulating activity glycopeptide glycyrrhizic glutamic acid preparation, licorice glycyrrhiza glabra glycopeptide glutamate preparation immunomodulator, Amino Acids, Peptides, and Proteins: Poly(Amino Acids) and Peptides and other aspects.Product Details of 53838-27-0

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On February 28, 2010, Sicherl, Frank; Cupido, Tommaso; Albericio, Fernando published an article.Quality Control of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate The title of the article was A novel dipeptidomimetic containing a cyclic threonine. And the article contained the following:

An efficient and simple two-step procedure for the formation of hydroxy-Freidinger lactams is presented. The methodol. allows assembly of the cyclic threonine motif (cThr) in solution and on solid support during conventional peptide synthesis. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).Quality Control of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate

The Article related to peptidomimetic cyclic threonine synthesis hydroxy freidinger lactam, epoxide ring opening lactamization lactam solid phase peptide synthesis, Amino Acids, Peptides, and Proteins: Poly(Amino Acids) and Peptides and other aspects.Quality Control of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On May 31, 2002, Gutheil, William G.; Xu, Qingchai published an article.HPLC of Formula: 53838-27-0 The title of the article was N-to-C solid-phase peptide and peptide trifluoromethylketone synthesis using amino acid tert-butyl esters. And the article contained the following:

Solid-phase peptide synthesis in the N-to-C direction, opposite to the classical C-to-N direction of peptide, synthesis, provides the synthetically versatile C-terminal carboxyl group for further modification into C-terminally modified peptide mimetics. These are of general interest as potential bioactive agents, particularly as protease inhibitors. Elaboration of peptide mimetics on the solid-phase would facilitate synthesis of peptide mimetic combinatorial libraries. This report describes an effective strategy for solid-phase inverse peptide synthesis based on readily available amino acid tert-Bu esters. The potential of this approach for peptide mimetic synthesis is demonstrated by the solid-phase synthesis of two peptide trifluoromethylketones. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).HPLC of Formula: 53838-27-0

The Article related to solid phase inverse peptide synthesis amino acid butyl ester, peptidomimetic peptide trifluoromethylketone solid phase inverse synthesis, Amino Acids, Peptides, and Proteins: Poly(Amino Acids) and Peptides and other aspects.HPLC of Formula: 53838-27-0

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics